ImmunoGen aims to conduct Phase I study of lymphoma drug

09/25/2011 | American City Business Journals

ImmunoGen submitted an application to the FDA seeking approval to launch a Phase I trial of IMGN529, a drug candidate for patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company said the drug contains an antibody that facilitates death of tumor cells by delivering anti-cancer agent DM1 directly to B cells.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR